Brii Biosciences Limited
BRIBF
$0.2406
$0.00944.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -99.41% | -98.80% |
| Total Other Revenue | -11.95% | -37.70% | -55.59% | -41.20% | -24.47% |
| Total Revenue | -12.93% | -54.84% | -72.80% | -64.54% | -55.31% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -12.93% | -54.84% | -72.80% | -64.54% | -55.31% |
| SG&A Expenses | 1.20% | 3.42% | 4.58% | 0.08% | -4.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.74% | -17.88% | -10.73% | -10.72% | -10.88% |
| Operating Income | 27.06% | 10.72% | -8.26% | -3.56% | 0.64% |
| Income Before Tax | -166.66% | -49.91% | 18.76% | 46.47% | 64.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -166.66% | -49.91% | 18.76% | 46.47% | 64.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -56.96% | 123.99% | 191.99% | 1,428.07% | 38.49% |
| Net Income | -178.67% | -49.30% | 21.72% | 48.15% | 65.42% |
| EBIT | 27.06% | 10.72% | -8.26% | -3.56% | 0.64% |
| EBITDA | 26.83% | 10.22% | -9.25% | -4.17% | 0.33% |
| EPS Basic | -177.36% | -48.59% | 22.07% | 48.49% | 65.62% |
| Normalized Basic EPS | 1.36% | 24.36% | 42.24% | 43.85% | 44.99% |
| EPS Diluted | -177.36% | -48.59% | 22.07% | 48.49% | 65.62% |
| Normalized Diluted EPS | 1.36% | 24.36% | 42.24% | 43.85% | 44.99% |
| Average Basic Shares Outstanding | 0.29% | 0.35% | 0.40% | 0.52% | 0.64% |
| Average Diluted Shares Outstanding | 0.29% | 0.35% | 0.40% | 0.52% | 0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |